Antithrombotic agents
Jeffrey I Weitz
McMaster University and the Thrombosis & Atherosclerosis Research Centre, Hamilton, Ontario, Canada
Search for more papers by this authorJeffrey I Weitz
McMaster University and the Thrombosis & Atherosclerosis Research Centre, Hamilton, Ontario, Canada
Search for more papers by this authorAdam J Mead PhD, FRCP, FRCPath, FMedSci
Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
Search for more papers by this authorMichael A Laffan DM, MRCP, FRCPath
Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK
Search for more papers by this authorGraham P Collins DPhil, FRCP, FRCPath
Department of Haematology, Oxford Cancer and Haematology Centre, Oxford, UK
Search for more papers by this authorDeborah Hay DPhil, MRCP, FRCPath
Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
Search for more papers by this authorA Victor Hoffbrand MA, DM, FRCP, FRCPath, FRCP (Edin), DSc, FMedSci
Emeritus Professor of Haematology Honorary Consultant Haematologist
University College London, London, UK
Royal Free Hospital, London, UK
Search for more papers by this authorSummary
Antithrombotic agents, which are widely used for the prevention and treatment of arterial and venous thrombosis, include antiplatelet drugs and anticoagulants. The antiplatelet agents include oral drugs such as thienopyridines (clopidogrel and prasugrel), ticagrelor, vorapaxar and aspirin, as well as parenteral agents such as cangrelor and glycoprotein IIb/IIIa antagonists. The anticoagulants include parenteral drugs such as heparin, low-molecular-weight heparin and fondaparinux and oral drugs such as warfarin and direct oral anticoagulants. This chapter reviews the mechanisms of action, indications, dosing and side effects of these antithrombotic agents.
Selected bibliography
- Anand SS , Caron F , Eikelboom JW et al . ( 2018 ) Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS Trial . Journal of the American College of Cardiology 71 : 2306 – 15 .
- Ansell J , Laulicht BE , Bakhru SH et al . ( 2021 ) Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants . Blood 137 : 115 – 125 .
- Barnes GD , Mouland E ( 2018 ) Peri-procedural management of oral anticoagulants in the DOAC era . Progress in Cardiovascular Diseases 60 : 600 – 6 .
- Bhatt DL , Pollock CV , Mazer CD et al . ( 2021 ) Bentracimab for ticagrelor reversal in patients undergoing urgent surgery NEJM Evidence : EVIDoa2100047
- Bonaca MP , Bauersachs RM , Anand SS et al . ( 2020 ) Rivaroxaban in peripheral artery disease after revascularization . The New England Journal of Medicine 382 : 1994 – 2000 .
- Connolly SJ , Crowther M , Eikelboom JW ( 2019 ) Full study report of andexanet alfa for bleeding associated with factor Xa Inhibitors The New England Journal of Medicine 380 : 1326 – 35 .
- Eikelboom JW , Connolly SJ , Bosch J et al . ( 2017 ) Rivaroxaban with or without aspirin in stable cardiovascular disease . The New England Journal of Medicine 377 : 1319 – 30 .
- Fredenburgh JC , Weitz JI ( 2021 ) New anticoagulants: moving beyond the direct oral anticoagulants . Journal of Thrombosis and Haemostasis 19 : 20 – 9 .
- Jourdi G , Godier A , Lordkipanidzé M et al . ( 2022 ) Antiplatelet therapy for atherothrombotic disease in 2022—from population to patient-centered approaches . Frontiers in Cardiovascular Medicine https://doi.org/10.3389/fcvm.2022.805525 .
- Lyman GH , Carrier M , Ay C et al . ( 2021 ) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer . Blood Advances 5 : 927 – 74 .
- Pollack Jr CV , Reilly PA , van Ryn J ( 2017 ) Idarucizumab for dabigatran reversal – full cohort analysis . The New England Journal of Medicine 377 : 431 – 41 .
- Schuyler Jones W , Mulder H , Wruck LM et al . ( 2021 ) Comparative effectiveness of aspirin dosing in cardiovascular disease . The New England Journal of Medicine 384 : 1981 – 90 .
-
Stevens SM
et al
. (
2021
)
Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report
.
Chest
(
https://doi.org/10.1016/j.chest.2021.07.055
).
10.1016/j.chest.2021.07.055 Google Scholar
- Tomaselli GF , Mahaffey KW , Cuker A et al . ( 2020 ) ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology task force on expert consensus decision pathways . Journal of the American College of Cardiology 76 : 594 – 622 .
